MBX vs MENS

MBX Biosciences, Inc. vs Jyong Biotech Ltd. — Valuation Comparison 2026

MBX

Biotechnology
MBX Biosciences, Inc.
Quality
4.5
out of 10
Value Trap
12
SAFE
Price
$31.90
Last close
Models
7/13
Active
VS

MENS

Biotechnology
Jyong Biotech Ltd.
Quality
2.3
out of 10
Value Trap
Price
$2.25
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType MBX Fair ValueMBX Upside MENS Fair ValueMENS Upside
Bayesian DCF Intrinsic $9.00 -71.8% $0.60 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $6.36 -80.1% $1.44 -33.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $0.17 -92.1%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MBX vs MENS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MBX vs MENS — Which Stock Is More Undervalued?

MBX scores higher with a 4.5/10 quality rating vs MENS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MBX Biosciences, Inc. (MBX) and Jyong Biotech Ltd. (MENS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MBX currently trades at $31.90 with a QOC of 4.5/10, while MENS trades at $2.25 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).